Vaccines that can rapidly induce strong and robust antibody-mediated immunity could improve protection from certain infectious diseases for which current vaccine formulations are inefficient. For indications such as anthrax and influenza, antibody production in vivo is a correlate of efficacy. Toll-like receptor (TLR) agonists are frequently studied for their role as vaccine adjuvants, largely because of their ability to enhance initiation of immune responses to antigens by activating dendritic cells. However, TLRs are also expressed on B cells and may contribute to effective B cell activation and promote differentiation into antigen-specific antibody producing plasma cells in vivo. We sought to discover an adjuvant system that could be use...
Background: We previously showed that the bacterial lipopeptide Pam3Cys-Ser-Ser, meanwhile establish...
Identifying safe and effective adjuvants is critical for the advanced development of protein-based v...
Effective vaccine adjuvants and formulations often fail to achieve FDA approval due to their adverse...
<div><p>Vaccines that can rapidly induce strong and robust antibody-mediated immunity could improve ...
Induction of antigen-specific cell-mediated immunity (CMI), as well as humoral immunity, is critical...
Despite the possibility of combining Toll-like receptor (TLR) ligands as adjuvants to improve vaccin...
Abstract Toll-like receptor (TLR) agonists improve vaccine immunogenicity and efficacy, but they are...
Vaccine efficacy is optimized by addition of immune adjuvants. However, although adjuvants have been...
The effects of adjuvants for increasing the immunogenicity of influenza vaccines are well known. How...
The development of new protein subunit vaccines has stimulated the search for improved adjuvants to ...
The efficacy of some vaccines is enhanced by the presence of adjuvants added to their formulations o...
The limited efficacy of seasonal influenza vaccines is usually attributed to ongoing variation in th...
<div><p>Binding of pattern recognition receptors (PRRs) by pathogen-associated molecular patterns (P...
Binding of pattern recognition receptors (PRRs) by pathogen-associated molecular patterns (PAMPs) ac...
Most commonly used adjuvants in vaccines are effective at elevating serum antibody titers but do not...
Background: We previously showed that the bacterial lipopeptide Pam3Cys-Ser-Ser, meanwhile establish...
Identifying safe and effective adjuvants is critical for the advanced development of protein-based v...
Effective vaccine adjuvants and formulations often fail to achieve FDA approval due to their adverse...
<div><p>Vaccines that can rapidly induce strong and robust antibody-mediated immunity could improve ...
Induction of antigen-specific cell-mediated immunity (CMI), as well as humoral immunity, is critical...
Despite the possibility of combining Toll-like receptor (TLR) ligands as adjuvants to improve vaccin...
Abstract Toll-like receptor (TLR) agonists improve vaccine immunogenicity and efficacy, but they are...
Vaccine efficacy is optimized by addition of immune adjuvants. However, although adjuvants have been...
The effects of adjuvants for increasing the immunogenicity of influenza vaccines are well known. How...
The development of new protein subunit vaccines has stimulated the search for improved adjuvants to ...
The efficacy of some vaccines is enhanced by the presence of adjuvants added to their formulations o...
The limited efficacy of seasonal influenza vaccines is usually attributed to ongoing variation in th...
<div><p>Binding of pattern recognition receptors (PRRs) by pathogen-associated molecular patterns (P...
Binding of pattern recognition receptors (PRRs) by pathogen-associated molecular patterns (PAMPs) ac...
Most commonly used adjuvants in vaccines are effective at elevating serum antibody titers but do not...
Background: We previously showed that the bacterial lipopeptide Pam3Cys-Ser-Ser, meanwhile establish...
Identifying safe and effective adjuvants is critical for the advanced development of protein-based v...
Effective vaccine adjuvants and formulations often fail to achieve FDA approval due to their adverse...